13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q3 2018. See the latest, Q2 2026 →
Reported value
$1.04B
−12% on the quarter before
Positions
17
3 new · 3 sold out
Top 10
95.1%
of the value
Est. gain
−$161.8M
on stocks held all quarter
Est. return
−14.5%
on those stocks since Q2 2018
Positions as of Sep 30, 2018, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2018. Striped tiles are options.
Largest buys
Since Q2 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Svmk Inc~$73.9MNew · 0.0% → 7.1%+4,608,705 shares
- Gritstone Oncology Inc~$13.2MNew · 0.0% → 1.3%+929,022 shares
- Spotify Technology S A~$1.7MNew · 0.0% → 0.2%+9,646 shares
Largest sells
Since Q2 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
Holdings
As of Sep 30, 2018. Changes are in shares against Jun 30, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jd Com IncSPON ADR CL A · shares 0% · price −33.0% | 33.9% | $353.6M | −$174.3M | ||||||||
| Arris Intl IncSHS · shares 0% · price +6.3% | 24.2% | $252.2M | +$15.0M | ||||||||
| DocuSignCOM · shares 0% · price −0.7% | 7.4% | $76.8M | −$556,000 | ||||||||
| Svmk IncCOM · shares New | 7.1% | $73.9M | — | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price +13.9% | 6.7% | $70.4M | +$8.6M | ||||||||
| ZscalerCOM · shares −48% · price +14.1% | 5.7% | $59.1M | +$7.3M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price −11.0% | 3.8% | $40.1M | −$5.0M | ||||||||
| Forty Seven IncCOM · shares 0% · price −6.7% | 2.2% | $23.1M | −$1.7M | ||||||||
| SnapCL A · shares 0% · price −35.2% | 2.1% | $22.2M | −$12.1M | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares 0% · price +14.5% | 2.1% | $21.9M | +$2.8M | ||||||||
| Gritstone Oncology IncCOM · shares New | 1.3% | $13.2M | — | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price +3.2% | 1.2% | $12.9M | +$403,000 | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price −28.4% | 1.1% | $11.7M | −$4.6M | ||||||||
| Cloudera IncCOM · shares −50% · price +29.4% | 0.72% | $7.5M | +$1.7M | ||||||||
| Pluralsight IncCL A · shares 0% · price +30.9% | 0.31% | $3.2M | +$766,000 | ||||||||
| Spotify Technology S ASHS · shares New | 0.17% | $1.7M | — | ||||||||
| Dropbox IncCL A · shares 0% · price −17.3% | 0.03% | $350,000 | −$73,000 | ||||||||
| Total · 17 positions | 100% | $1.04B | −$161.8M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2018 to Q3 2018: 14 stocks held throughout, down $161.8M (−14.5%).
- Arris Intl Inc+$15.0M+6%
- Arcus Biosciences Inc+$8.6M+14%
- Zscaler+$7.3M+14%
- Autolus Therapeutics Plc+$2.8M+14%
- Cloudera Inc+$1.7M+29%
- Forty Seven Inc−$1.7M−7%
- Spero Therapeutics Inc−$4.6M−28%
- Magenta Therapeutics Inc−$5.0M−11%
- Snap−$12.1M−35%
- Jd Com Inc−$174.3M−33%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |